| __timestamp | ADMA Biologics, Inc. | Agios Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 3742367 | 100371000 |
| Thursday, January 1, 2015 | 4311461 | 141827000 |
| Friday, January 1, 2016 | 6360761 | 220163000 |
| Sunday, January 1, 2017 | 29164321 | 292681000 |
| Monday, January 1, 2018 | 42194635 | 1397000 |
| Tuesday, January 1, 2019 | 39504238 | 1317000 |
| Wednesday, January 1, 2020 | 61291426 | 2805000 |
| Friday, January 1, 2021 | 79769341 | 18777000 |
| Saturday, January 1, 2022 | 118814535 | 1704000 |
| Sunday, January 1, 2023 | 169273000 | 9504000 |
| Monday, January 1, 2024 | 4165000 |
Unlocking the unknown
In the dynamic world of biotechnology, understanding cost structures is crucial for investors and stakeholders. This analysis delves into the cost of revenue trends for ADMA Biologics, Inc. and Agios Pharmaceuticals, Inc. over the past decade. From 2014 to 2023, ADMA Biologics saw a staggering increase of over 4,400% in its cost of revenue, peaking in 2023. This reflects the company's aggressive expansion and scaling efforts. In contrast, Agios Pharmaceuticals experienced a dramatic 97% decline from its 2017 peak, indicating a strategic shift or operational efficiency improvements. The year 2017 marked a pivotal point for both companies, with Agios reaching its highest cost of revenue, while ADMA began its upward trajectory. These trends highlight the contrasting strategies and market responses of these two biotech firms, offering valuable insights for industry observers.
Johnson & Johnson vs Agios Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Intra-Cellular Therapies, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Agios Pharmaceuticals, Inc.'s Expenses
Comparing Cost of Revenue Efficiency: Pharming Group N.V. vs Agios Pharmaceuticals, Inc.
ADMA Biologics, Inc. vs CRISPR Therapeutics AG: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: ADMA Biologics, Inc. vs Xenon Pharmaceuticals Inc.
Cost Insights: Breaking Down ADMA Biologics, Inc. and ACADIA Pharmaceuticals Inc.'s Expenses
Analyzing Cost of Revenue: ADMA Biologics, Inc. and Perrigo Company plc
Cost of Revenue: Key Insights for ADMA Biologics, Inc. and Veracyte, Inc.
Cost of Revenue Trends: ADMA Biologics, Inc. vs HUTCHMED (China) Limited
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Agios Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd.